{"result": "{\n    \"title\": \"GeparQuinto Community\",\n    \"summary\": \"The GeparQuinto community revolves around the GeparQuinto clinical trial, which investigated the effectiveness of neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer. The community consists of researchers involved in the study, including Cristofanilli M, von Minckwitz G, Untch M, Loibl S, Rezai M, and others. The study was published in J Clin Oncol and Lancet Oncol.\",\n    \"rating\": 6.5,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for significant medical advancements and implications for patient treatment.\",\n    \"findings\": [\n        {\n            \"summary\": \"GeparQuinto Clinical Trial\",\n            \"explanation\": \"The GeparQuinto clinical trial is a randomized neoadjuvant phase 3 study that investigated the effectiveness of neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer. The study was conducted by GBG 44 and published in J Clin Oncol and Lancet Oncol [Data: Entities (734, 735, 736, 737, 738, 739); Relationships (239, 247, 233, 244, 228, 236, 246, 229, 230, 231, 232, 238, 241, 237, 248, 245, 234, 235, 240, 242, 243)].\"\n        },\n        {\n            \"summary\": \"Researchers Involved\",\n            \"explanation\": \"The GeparQuinto study involved several researchers, including Cristofanilli M, von Minckwitz G, Untch M, Loibl S, Rezai M, and others. These researchers have contributed to the study's design, implementation, and publication [Data: Entities (734, 735, 736, 737, 738, 739); Relationships (239, 247, 233, 244, 228, 236, 246, 229, 230, 231, 232, 238, 241, 237, 248, 245, 234, 235, 240, 242, 243)].\"\n        },\n        {\n            \"summary\": \"Study Design and Implementation\",\n            \"explanation\": \"The GeparQuinto study was designed to investigate the effectiveness of neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer. The study was conducted by GBG 44 and involved the recruitment of patients with breast cancer [Data: Entities (734, 735, 736, 737, 738, 739); Relationships (239, 247, 233, 244, 228, 236, 246, 229, 230, 231, 232, 238, 241, 237, 248, 245, 234, 235, 240, 242, 243)].\"\n        },\n        {\n            \"summary\": \"Study Results and Implications\",\n            \"explanation\": \"The GeparQuinto study found that neoadjuvant chemotherapy with trastuzumab or lapatinib was effective in patients with human epidermal growth factor receptor 2-positive breast cancer. The study's results have significant implications for patient treatment and may lead to improved outcomes [Data: Entities (734, 735, 736, 737, 738, 739); Relationships (239, 247, 233, 244, 228, 236, 246, 229, 230, 231, 232, 238, 241, 237, 248, 245, 234, 235, 240, 242, 243)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n173,\"\"\"GEPARQUINTO\"\"\",\"Here is a comprehensive summary of the data:\n\nGeparQuinto is a randomized neoadjuvant phase 3 clinical trial that investigated the effectiveness of neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer. Specifically, the trial compared lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy to determine their relative efficacy in this patient population.\",21\r\n735,\"\"\"BOUSSEN H\"\"\",\"\"\"Boussen H is a researcher involved in the GeparQuinto study.\"\"\",1\r\n737,\"\"\"DESILVIO M\"\"\",\"Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.\",1\r\n734,\"\"\"FASCHING PA\"\"\",\"\"\"Fasching PA is a researcher involved in the GeparQuinto study.\"\"\",1\r\n740,\"\"\"G5\"\"\",\"\"\"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.\"\"\",1\r\n728,\"\"\"GBG 44\"\"\",\"Here is a comprehensive summary of the data:\n\nGBG 44 is a clinical trial that investigated the efficacy of lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy. Additionally, GBG 44 is the organization responsible for conducting the GeparQuinto study.\",1\r\n731,\"\"\"GERBER B\"\"\",\"\"\"Gerber B is a researcher involved in the GeparQuinto study.\"\"\",1\r\n732,\"\"\"SCHEM C\"\"\",\"\"\"Schem C is a researcher involved in the GeparQuinto study.\"\"\",1\r\n736,\"\"\"ZAKS T\"\"\",\"Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.\",1\r\n738,\"\"\"SALAZAR V\"\"\",\"Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.\",1\r\n739,\"\"\"SPECTOR N\"\"\",\"Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.\",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n239,\"\"\"GEPARQUINTO\"\"\",\"\"\"CRISTOFANILLI M\"\"\",\"\"\"Cristofanilli M is a researcher involved in the GeparQuinto study.\"\"\",39\r\n247,\"\"\"GEPARQUINTO\"\"\",\"\"\"J CLIN ONCOL\"\"\",\"\"\"GeparQuinto is published in J Clin Oncol.\"\"\",31\r\n233,\"\"\"GEPARQUINTO\"\"\",\"\"\"VON MINCKWITZ G\"\"\",\"\"\"von Minckwitz G is a researcher involved in the GeparQuinto study.\"\"\",30\r\n244,\"\"\"GEPARQUINTO\"\"\",\"\"\"UNTCH M\"\"\",\"\"\"Untch M is a researcher involved in the GeparQuinto study.\"\"\",29\r\n228,\"\"\"GEPARQUINTO\"\"\",\"\"\"LOIBL S\"\"\",\"\"\"Loibl S is a researcher involved in the GeparQuinto study.\"\"\",25\r\n236,\"\"\"GEPARQUINTO\"\"\",\"\"\"REZAI M\"\"\",\"\"\"Rezai M is a researcher involved in the GeparQuinto study.\"\"\",24\r\n246,\"\"\"GEPARQUINTO\"\"\",\"\"\"LANCET ONCOL\"\"\",\"\"\"GeparQuinto is published in Lancet Oncol.\"\"\",24\r\n229,\"\"\"GEPARQUINTO\"\"\",\"\"\"BISCHOFF J\"\"\",\"\"\"Bischoff J is a researcher involved in the GeparQuinto study.\"\"\",23\r\n230,\"\"\"GEPARQUINTO\"\"\",\"\"\"EIDTMANN H\"\"\",\"\"\"Eidtmann H is a researcher involved in the GeparQuinto study.\"\"\",23\r\n231,\"\"\"GEPARQUINTO\"\"\",\"\"\"KAUFMANN M\"\"\",\"\"\"Kaufmann M is a researcher involved in the GeparQuinto study.\"\"\",23\r\n232,\"\"\"GEPARQUINTO\"\"\",\"\"\"BLOHMER JU\"\"\",\"\"\"Blohmer JU is a researcher involved in the GeparQuinto study.\"\"\",23\r\n238,\"\"\"GEPARQUINTO\"\"\",\"\"\"BOUSSEN H\"\"\",\"\"\"Boussen H is a researcher involved in the GeparQuinto study.\"\"\",22\r\n241,\"\"\"GEPARQUINTO\"\"\",\"\"\"DESILVIO M\"\"\",\"\"\"DeSilvio M is a researcher involved in the GeparQuinto study.\"\"\",22\r\n237,\"\"\"GEPARQUINTO\"\"\",\"\"\"FASCHING PA\"\"\",\"\"\"Fasching PA is a researcher involved in the GeparQuinto study.\"\"\",22\r\n248,\"\"\"GEPARQUINTO\"\"\",\"\"\"G5\"\"\",\"\"\"G5 is a study related to GeparQuinto.\"\"\",22\r\n245,\"\"\"GEPARQUINTO\"\"\",\"\"\"GBG 44\"\"\",\"\"\"GeparQuinto is conducted by GBG 44.\"\"\",22\r\n234,\"\"\"GEPARQUINTO\"\"\",\"\"\"GERBER B\"\"\",\"\"\"Gerber B is a researcher involved in the GeparQuinto study.\"\"\",22\r\n235,\"\"\"GEPARQUINTO\"\"\",\"\"\"SCHEM C\"\"\",\"\"\"Schem C is a researcher involved in the GeparQuinto study.\"\"\",22\r\n240,\"\"\"GEPARQUINTO\"\"\",\"\"\"ZAKS T\"\"\",\"\"\"Zaks T is a researcher involved in the GeparQuinto study.\"\"\",22\r\n242,\"\"\"GEPARQUINTO\"\"\",\"\"\"SALAZAR V\"\"\",\"\"\"Salazar V is a researcher involved in the GeparQuinto study.\"\"\",22\r\n243,\"\"\"GEPARQUINTO\"\"\",\"\"\"SPECTOR N\"\"\",\"\"\"Spector N is a researcher involved in the GeparQuinto study.\"\"\",22\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}